| TA33 |
Colorectal cancer (advanced) - irinotecan, oxaliplatin & raltitrexed (TA33) (replaced by TA93) |
|
-
-
The clinical effectiveness and cost effectiveness of irinotecan, oxaliplatin and raltitrexed for colorectal cancer
This guidance has been replaced by TA93 Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (repaced by CG131)
-
Other information
How this guidance was produced
Background information
This page was last updated: 20 December 2011
-
-
Guidance formats
-
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
